These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31555260)

  • 1. Sensitization of Tumors for Attack by Virus-Specific CD8+ T-Cells Through Antibody-Mediated Delivery of Immunogenic T-Cell Epitopes.
    Sefrin JP; Hillringhaus L; Mundigl O; Mann K; Ziegler-Landesberger D; Seul H; Tabares G; Knoblauch D; Leinenbach A; Friligou I; Dziadek S; Offringa R; Lifke V; Lifke A
    Front Immunol; 2019; 10():1962. PubMed ID: 31555260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8
    Jung K; Son MJ; Lee SY; Kim JA; Ko DH; Yoo S; Kim CH; Kim YS
    Mol Cancer; 2022 Apr; 21(1):102. PubMed ID: 35459256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy.
    Millar DG; Ramjiawan RR; Kawaguchi K; Gupta N; Chen J; Zhang S; Nojiri T; Ho WW; Aoki S; Jung K; Chen I; Shi F; Heather JM; Shigeta K; Morton LT; Sepulveda S; Wan L; Joseph R; Minogue E; Khatri A; Bardia A; Ellisen LW; Corcoran RB; Hata AN; Pai SI; Jain RK; Fukumura D; Duda DG; Cobbold M
    Nat Biotechnol; 2020 Apr; 38(4):420-425. PubMed ID: 32042168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces.
    van der Wulp W; Luu W; Ressing ME; Schuurman J; van Kasteren SI; Guelen L; Hoeben RC; Bleijlevens B; Heemskerk MHM
    MAbs; 2024; 16(1):2329321. PubMed ID: 38494955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenic epitopes fused to cationic peptide bound to oligonucleotides facilitate Toll-like receptor 9-dependent, but CD4+ T cell help-independent, priming of CD8+ T cells.
    Schirmbeck R; Riedl P; Zurbriggen R; Akira S; Reimann J
    J Immunol; 2003 Nov; 171(10):5198-207. PubMed ID: 14607920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-mediated delivery of viral epitopes to redirect EBV-specific CD8
    van der Wulp W; Remst DFG; Kester MGD; Hagedoorn RS; Parren PWHI; van Kasteren SI; Schuurman J; Hoeben RC; Ressing ME; Bleijlevens B; Heemskerk MHM
    Cancer Gene Ther; 2024 Jan; 31(1):58-68. PubMed ID: 37945970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells.
    Schmittnaegel M; Hoffmann E; Imhof-Jung S; Fischer C; Drabner G; Georges G; Klein C; Knoetgen H
    Mol Cancer Ther; 2016 Sep; 15(9):2130-42. PubMed ID: 27353170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination.
    Hulett TW; Jensen SM; Wilmarth PA; Reddy AP; Ballesteros-Merino C; Afentoulis ME; Dubay C; David LL; Fox BA
    J Immunother Cancer; 2018 Apr; 6(1):27. PubMed ID: 29618380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted coating with antigenic peptide renders tumor cells susceptible to CD8(+) T cell-mediated killing.
    Kang TH; Ma B; Wang C; Wu TC; Hung CF
    Mol Ther; 2013 Mar; 21(3):542-53. PubMed ID: 23183537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice.
    Kavunja HW; Lang S; Sungsuwan S; Yin Z; Huang X
    Cancer Immunol Immunother; 2017 Apr; 66(4):451-460. PubMed ID: 28011995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep.
    Rojas JM; Rodríguez-Calvo T; Peña L; Sevilla N
    Vaccine; 2011 Sep; 29(40):6848-57. PubMed ID: 21807057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Foreign antigenic peptides delivered to the tumor as targets of cytotoxic T cells.
    Wei WZ; Ratner S; Shibuya T; Yoo G; Jani A
    J Immunol Methods; 2001 Dec; 258(1-2):141-50. PubMed ID: 11684131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple antigenic peptides based on H-2K(b)-restricted CTL epitopes from murine heparanase induce a potent antitumor immune response in vivo.
    Tang XD; Wang GZ; Guo J; Lü MH; Li C; Li N; Chao YL; Li CZ; Wu YY; Hu CJ; Fang DC; Yang SM
    Mol Cancer Ther; 2012 May; 11(5):1183-92. PubMed ID: 22442309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico analysis of MHC-I restricted epitopes of Chikungunya virus proteins: Implication in understanding anti-CHIKV CD8(+) T cell response and advancement of epitope based immunotherapy for CHIKV infection.
    Pratheek BM; Suryawanshi AR; Chattopadhyay S; Chattopadhyay S
    Infect Genet Evol; 2015 Apr; 31():118-26. PubMed ID: 25643869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
    Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM
    J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.
    Otahal P; Hutchinson SC; Mylin LM; Tevethia MJ; Tevethia SS; Schell TD
    J Immunol; 2005 Jul; 175(2):700-12. PubMed ID: 16002665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.
    Altenburg AF; van de Sandt CE; van Trierum SE; De Gruyter HLM; van Run PRWA; Fouchier RAM; Roose K; Saelens X; Volz A; Sutter G; de Vries RD; Rimmelzwaan GF
    J Virol; 2016 Nov; 90(22):10209-10219. PubMed ID: 27581985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.